WuXi NextCODE Genomics:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:WuXi NextCODE Genomics - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10609
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
WuXi NextCODE Genomics USA Inc (WuXi NextCODE), a subsidiary of Wuxi Pharmatech (Cayman) Inc, is a genomic information company that offers competencies in generating, organizing, mining, sharing and applying genomic data. The company develops gene sequence analysis platform and database architecture, which enables clinicians and researchers across the globe to use the power of next-generation sequencing data to better diagnose and treat diseases. WuXi NextCODE’s services comprise genome analysis and interpretation, big data management and storage, custom integration and next generation sequencing. It has operations in Shanghai, Cambridge and Reykjavik. WuXi NextCODE is headquartered in Cambridge, Massachusetts, the US.

WuXi NextCODE Genomics – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
WuXi NextCODE Genomics, Medical Devices Deals, 2012 to YTD 2018 9
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
DNAnexus Raises USD58 Million in Equity Financing 11
WuXi NextCODE Raises Additional USD165 Million in Series B Financing 13
NextCode Health Raises USD15 Million in Series A Financing 14
Partnerships 15
WuXi NextCode Enters into Partnership with Rhythm Pharma 15
AbbVie Enters into Agreement with Genomics Medicine Ireland and WuXi NextCODE Genomics 16
Genomics England Enters into Contract Agreement with WuXi NextCODE 17
SA1KCGP, WuXi NextCODE and START Enter into Partnership 18
WuXi NextCODE Genomics Enters into Agreement with Sidra Medical and Research Center 19
NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 20
Acquisition 21
WuXi PharmaTech Acquires NextCODE Health for USD65 Million 21
WuXi NextCODE Genomics – Key Competitors 22
WuXi NextCODE Genomics – Key Employees 23
WuXi NextCODE Genomics – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Corporate Communications 25
Apr 15, 2018: WuXi NextCODE Appoints Richard Williams As Managing Director And Head Of Oncology Programs 25
Mar 12, 2018: WuXi NextCODE Appoints Rob Brainin As Chief Executive Officer 26
Feb 28, 2017: WuXi NextCODE Appoints Hannes Smarason as CEO, John Long as CFO, and Alex Fowkes as COO 27
Government and Public Interest 28
Feb 28, 2017: China plans leading role in ‘precision medicine’ field 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Key Facts 2
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
WuXi NextCODE Genomics, Deals By Therapy Area, 2012 to YTD 2018 8
WuXi NextCODE Genomics, Medical Devices Deals, 2012 to YTD 2018 9
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
DNAnexus Raises USD58 Million in Equity Financing 11
WuXi NextCODE Raises Additional USD165 Million in Series B Financing 13
NextCode Health Raises USD15 Million in Series A Financing 14
WuXi NextCode Enters into Partnership with Rhythm Pharma 15
AbbVie Enters into Agreement with Genomics Medicine Ireland and WuXi NextCODE Genomics 16
Genomics England Enters into Contract Agreement with WuXi NextCODE 17
SA1KCGP, WuXi NextCODE and START Enter into Partnership 18
WuXi NextCODE Genomics Enters into Agreement with Sidra Medical and Research Center 19
NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 20
WuXi PharmaTech Acquires NextCODE Health for USD65 Million 21
WuXi NextCODE Genomics, Key Competitors 22
WuXi NextCODE Genomics, Key Employees 23
WuXi NextCODE Genomics, Other Locations 24

List of Figures
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
WuXi NextCODE Genomics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
WuXi NextCODE Genomics, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[WuXi NextCODE Genomics:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HKS Inc:企業の戦略・SWOT・財務情報
    HKS Inc - Strategy, SWOT and Corporate Finance Report Summary HKS Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • PT Bank CIMB Niaga Tbk (BNGA)
    PT Bank CIMB Niaga Tbk (BNGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Eisai Inc:企業の戦略的SWOT分析
    Eisai Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Agilent Technologies Inc (A):企業の財務・戦略的SWOT分析
    Agilent Technologies Inc (A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Automotive Holdings Group Limited:企業のM&A・事業提携・投資動向
    Automotive Holdings Group Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Automotive Holdings Group Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Metorex Ltd:企業の戦略・SWOT・財務情報
    Metorex Ltd - Strategy, SWOT and Corporate Finance Report Summary Metorex Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Boone Electric Cooperative:企業の戦略的SWOT分析
    Boone Electric Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • ADx NeuroSciences NV:企業の製品パイプライン分析2018
    Summary ADx NeuroSciences NV (ADx NeuroSciences) is a medical device company that develops proprietary biomarkers for various neurodegenerative diseases. The company offers biomarkers for Alzheimer’s disease, Parkinson’s disease and traumatic brain injury. It also develops and commercializes analyti …
  • Northern Minerals Ltd (GPP):企業の財務・戦略的SWOT分析
    Summary Northern Minerals Ltd (Northern Minerals) formerly known as Greenpower Energy Limited, is a mining, exploration and development company. The company’s business activities include acquisition, exploration, and development of petroleum, mineral and hydrothermal exploration properties. It explo …
  • UnitedHealth Group Inc (UNH):企業の財務・戦略的SWOT分析
    UnitedHealth Group Inc (UNH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • PT Bank Central Asia Tbk:企業の戦略・SWOT・財務情報
    PT Bank Central Asia Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Bank Central Asia Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Siemens Healthcare GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Siemens Healthcare GmbH d/b/a Siemens Healthineers, a subsidiary of Siemens AG, is a global medical device company that designs, develops, manufactures and distributes medical devices and technologies for diagnostic markets. Its major products include healthcare IT and medical infrastructure …
  • Welbilt, Inc. (WBT):企業の財務・戦略的SWOT分析
    Welbilt, Inc. (WBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Rigel Pharmaceuticals Inc (RIGL):製薬・医療:M&Aディール及び事業提携情報
    Summary Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease me …
  • University Hospitals-製薬・医療分野:企業M&A・提携分析
    Summary University Hospitals is a healthcare service provider that offers patient-centered medical care and education services. The center includes network of specialty care physicians, skilled nursing, elder health, rehabilitation and home care services, managed care and insurance programs, occupat …
  • Genome British Columbia:医療機器:M&Aディール及び事業提携情報
    Summary Genome British Columbia (Genome BC) is a non-profit medical research organization that conducts genomics and proteomics research, and offers science and technology solutions. The organization provides prognostic, new diagnostic, and therapeutic tools for use in personalized medicine. It also …
  • DNO ASA (DNO):石油・ガス:M&Aディール及び事業提携情報
    Summary DNO ASA (DNO) is an oil and gas company that provides mineral properties exploration and development services. The company's services include selective and targeted drilling, fractured carbonate plays that are characteristic of the MENA region. It also provides operations in petroleum, shipp …
  • OncoMed Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    OncoMed Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's OncoMed Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Delta Air Lines Inc:戦略・SWOT・企業財務分析
    Delta Air Lines Inc - Strategy, SWOT and Corporate Finance Report Summary Delta Air Lines Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Partner Reinsurance Asia Pte. Ltd.
    Partner Reinsurance Asia Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Partner Reinsurance Asia Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆